Young people without diabetes lose weight faster, a new study on GLP-1 drugs may surprise you.

News Topical, Digital Desk : A study conducted in India on new-generation weight loss medications has revealed that people without diabetes, and younger patients, experience rapid weight loss. This study is the first in India to examine the effects of these medications in real-world settings on overweight and obese individuals. The research involved 150 individuals who received injectable drugs like semaglutide and tirzepatide for six months. Both drugs belong to GLP-1 therapy, originally developed for the treatment of type 2 diabetes but now also being used to treat obesity. The results of this study were published in the Indian Journal of Endocrinology and Metabolism.

How much weight did participants lose?
According to the study, approximately 41 percent of participants lost more than 10 percent of their weight. The overall average weight loss rate was 8.2 percent. The study also showed a clear difference between those with and without diabetes. Those without diabetes experienced an average weight loss of 11.21 percent, while those with diabetes experienced a weight loss of 5.48 percent.

Which medication was more effective?
The study also found that patients taking tirzepatide experienced a faster weight loss rate. The average weight loss with this medication was 8.60 percent, compared to 5.62 percent for those taking semaglutide. Furthermore, patients who had never previously taken GLP-1 therapy experienced faster weight loss.

The study also showed
that age has a faster effect on weight loss in younger patients. In particular, weight loss goals of more than 10 percent were achieved more quickly in younger and younger patients. However, diabetes did not significantly impact weight loss below 10 percent. Furthermore, the study found that weight loss of more than 10 percent took an average of 9.5 months. Experts say that the full effect of these medications usually takes 12 to 18 months to show.

The study also revealed a connection between diabetes and obesity. 

The study also revealed that weight loss is relatively difficult for patients who have diabetes and obesity. Experts say that Indian patients are more prone to metabolic problems and insulin resistance. Furthermore, diabetic patients are often already taking multiple medications, including insulin. This slows down weight loss. It is being reported that these results come at a time when the patent for semaglutide has expired, paving the way for several generic versions in India's rapidly growing anti-obesity market. This has further increased the sales of Hindi medicines in the country. According to an estimate, approximately 101 million people in India suffer from diabetes, 254 million suffer from generalized obesity, and 35.1 percent suffer from abdominal obesity. Doctors believe this is due to changing eating habits and increasingly sedentary lifestyles.

Read More: Morning Heel Pain: You feel pain in your heels as soon as you wake up in the morning.